Added successfully to RFQ list

Added successfully to compare list

Our clients

We utilise CRISPR/Cas9 technology to manipulate the host’s genome, in order to understand the function of a gene of interest (GOI). In a simplest installation, a choice of selected single guide RNAs (sgRNAs) will direct the Cas9 nuclease to a sequence-specific site on a GOI, introducing indels through nonhomologous end joining (NHEJ), leading to a complete gene inactivation. If knock-out is viable, we can assess its phenotype in comparison to its wildtype counterpart. This in turn will yield information on the changes that occur upon loss of function of a GOI validating target’s involvement in a studied cellular pathway or a disease model. Knock-out can also be used to confirm engagement of a small molecule with a target, as well as its off-target effects.

Additionally, a combination of an sgRNA and a DNA template, fuelled by homology-directed repair (HDR), can allow us to precisely edit a defined endogenous amino acid(s) with an assumed function, augmenting final gene product, system’s phenotype, and/or specificity of a given small molecule binding to a target.

We can introduce indels, point mutations, tags, and protein markers via CRISPR/Cas9-mediated NHEJ or HDR to validate targets and small molecules engagement in cells, complemented by a choice of downstream readout assays (including gene-reporters, immuno-assays, imaging analysis). 

o2h team can:

  • Design sgRNAs and DNA repair templates
  • Perform gene editing in mammalian cells and generate clonal population
  • Assess the phenotype of knock-out or knock-in cells with a choice of redouts (including gene-reporters, immuno-assays, imaging analysis)
  • Validate targets and their engagement with small molecules
  • Conduct functional mutagenesis analysis of the endogenous amino acids
  • Introduce tags and markers on an endogenous protein for downstream application in biochemical, biophysical or imaging analysis

To know more about our biology services offering or to request our brochure, please reach out to us at discovery@o2h.com.

our team

prashant shah

Prashant Shah

CEO - o2h discovery and Co-Founder - o2h group

Prashant's Biography

Read more

Prashant Shah

CEO - o2h discovery and Co-Founder - o2h group

Prashant is a serial entrepreneur in life sciences and tech in which one of those companies was acquired by a public company. He is currently active in seed investing (a portfolio of ~50 companies), product/IP development, services, and building lab/office infrastructure. The early career was with the Strategy group at Accenture. He has a BEng, an MSc, in which he worked on the Human Genome Program at the Sanger Centre, and an MPhil in Management from the Judge Institute. Prashant is also a General Partner in the o2h SEIS/EIS Human Health Funds.


Connect on linkedin

Sunil

Sunil Shah

CEO - o2h Ventures and Co-Founder - o2h discovery

Sunil's Biography

Read more

Sunil Shah

CEO - o2h Ventures and Co-Founder - o2h discovery

A serial entrepreneur having begun a career in the Life Sciences team at PA Consulting group followed by co-founding two companies in the information technology and life sciences sector. The second of these companies, Oxygen Healthcare Ltd was acquired by Piramal Enterprises Ltd (BSE: PEL). Sunil co-founded o2h ventures which involves discovery services / collaborations, seeding drug discovery, academic in-licensing and biotechnology incubation. Sunil has a degree in Biochemistry and an MBA from Cambridge University


Connect on linkedin

Andy Morley

Andy Morley

Chief Scientific Officer

Andy's Biography

Read more

Andy Morley

Chief Scientific Officer

Andy is a highly experienced and accomplished Medicinal Chemist with over 25 years of experience in major pharmaceutical companies such as Sanofi-Aventis and AstraZeneca. He has extensive experience across all phases of drug discovery and has played a key role in the development of five candidates that have reached clinical trials. Andy is a prolific author and inventor, with over 55 publications and patents to his name. Since 2013, he has been working full-time with o2h Limited, where he leads the scientific evaluation of investment opportunities and provides scientific support. He has also served as CSO for two early-stage collaborations within the o2h Ventures portfolio, demonstrating his ability to successfully guide drug discovery projects from concept to clinical development.


Connect on linkedin

David Davies - o2h

David Davies

Head of Medicinal Chemistry

David's Biography

Read more

David Davies

Head of Medicinal Chemistry

David Davies has 25 years of experience in medicinal chemistry within the pharmaceutical industry with a focus on the antibacterial area (clavulanates, penicillinates, pseudomonates and bacterial topoisomerase inhibitors). He previously worked at GSK and currently holds a part-time academic position at University College London (UCL). He served as the Head of Medicinal Chemistry at Antabio for nearly a decade, specialising in antibacterial research, and has extensive experience managing chemistry projects in multiple countries including France, UK, India and China. He is the inventor of 40 patents and has authored 37 publications.


Connect on linkedin

o2h group launched revolutionary project management app for drug discovery

o2h group launched revolutionary project management app for drug discovery. The app’s full suite of project management tools is available exclusively to live project collaborators and a lighter version is open for researchers looking for a quote for the synthesis of small molecules.

the influencer biotech bootcamp

Hauxton House, Mill Scitech Park, Cambridge

The world’s first biotech bootcamp, including the quintet influencer community that is the creative force driving biotech.

View more

latest news

Read about some of the most recent developments including research collaborations at o2h discovery

speak to a member of our team

Contact Us